Pruritus Therapeutics Market By Disease Type (Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, and Others), By Product (Corticosteroids, Antihistamines, Immunosuppressant, Calcineurin Inhibitors, Local Anesthetics, Counterirritants, and Others), By Distribution Channel (Hospital Pharmacies, Online Providers and Drug Stores & Retail Pharmacies), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Report Overview

The Pruritus Therapeutics Market size is expected to be worth around US$ 13.7 billion by 2033 from US$ 8.9 billion in 2023, growing at a CAGR of 4.4% during the forecast period 2024 to 2033.

Increasing awareness of the impact of pruritus on quality of life drives significant growth in the pruritus therapeutics market, particularly for conditions such as atopic dermatitis and chronic liver diseases. The prevalence of pruritus is notably high among various populations, with the National Eczema Association reporting that approximately 9.6 million children in the United States under 18 suffer from atopic dermatitis, one-third of whom experience moderate to severe symptoms.

As healthcare providers seek effective treatment options, recent innovations in therapeutic agents have expanded available solutions for managing this challenging symptom. In July 2021, Albireo Pharma, Inc. introduced Bylvay, an FDA-approved medication designed specifically to treat pruritus associated with progressive familial intrahepatic cholestasis (PFIC). This launch highlights a growing trend toward developing targeted therapies that address the underlying causes of pruritus rather than merely alleviating symptoms.

Additionally, the rising focus on personalized medicine opens new opportunities for customized treatment plans tailored to individual patient needs. Advances in formulation technologies and delivery systems further enhance drug efficacy and patient adherence, paving the way for improved outcomes. As more pharmaceutical companies invest in research and development within this niche market, the pruritus therapeutics landscape will likely continue to evolve, offering new hope to those affected by chronic itching.

Key Takeaways

• In 2023, the market for Pruritus Therapeutics generated a revenue of US$ 8.9 billion, with a CAGR of 4.4%, and is expected to reach US$ 13.7 billion by the year 2033.
• The disease type segment is divided into atopic dermatitis, allergic contact dermatitis, urticaria, and others, with atopic dermatitis taking the lead in 2023 with a market share of 52.4%.
• Considering product, the market is divided into corticosteroids, antihistamines, immunosuppressant, calcineurin inhibitors, local anesthetics, counterirritants, and others. Among these, corticosteroids held a significant share of 45.8%.
• Furthermore, concerning the distribution channel segment, the market is segregated into hospital pharmacies, online providers and drug stores & retail pharmacies. The hospital pharmacies sector stands out as the dominant player, holding the largest revenue share of 59.8% in the Pruritus Therapeutics market.
• North America led the market by securing a market share of 38.9% in 2023.

Disease Type Analysis

The atopic dermatitis segment led in 2023, claiming a market share of 52.4% owing to the rising prevalence of this chronic skin condition. Increasing awareness of atopic dermatitis among both healthcare providers and patients is likely to drive demand for effective treatment options. The growing understanding of the underlying causes of this disease, including genetic and environmental factors, is anticipated to enhance the development of targeted therapies.

Additionally, the introduction of innovative biologics and topical treatments specifically designed for atopic dermatitis is projected to improve patient outcomes and compliance. The expanding patient population, particularly among children and young adults, will further contribute to the growth of this segment. As more individuals seek effective management strategies for this condition, the atopic dermatitis segment is likely to solidify its position in the overall therapeutic landscape.

Product Analysis

The corticosteroids held a significant share of 45.8% as these agents remain the first line of treatment for various skin conditions, including eczema and dermatitis. The effectiveness of corticosteroids in reducing inflammation and itching makes them a popular choice among healthcare providers, driving their continued usage. As the prevalence of skin disorders rises, the demand for corticosteroid formulations is expected to increase correspondingly.

Furthermore, advancements in drug delivery systems, such as improved topical formulations and combination therapies, are likely to enhance the efficacy and safety profiles of corticosteroids. The ongoing emphasis on developing more potent yet safer corticosteroid options is anticipated to attract more patients seeking relief from pruritic conditions. As a result, the corticosteroids segment is estimated to maintain a significant share within the overall therapeutics market for itch relief.

Distribution Channel Analysis

The hospital pharmacies segment had a tremendous growth rate, with a revenue share of 59.8% as healthcare institutions increasingly focus on providing comprehensive medication management. The rising prevalence of skin disorders requiring prescription medications drives the demand for hospital pharmacies to stock a wide range of effective treatments.

Moreover, the convenience and accessibility of medications offered through hospital pharmacies are likely to enhance patient adherence to prescribed therapies. The integration of pharmacy services within hospitals facilitates better patient care, as pharmacists can provide personalized medication counseling and monitoring.

Additionally, ongoing collaborations between healthcare providers and pharmacists are anticipated to improve treatment outcomes, further solidifying the role of hospital pharmacies in managing pruritus. As the healthcare landscape evolves, the importance of hospital pharmacies in the distribution of effective pruritus therapeutics is projected to increase, reflecting broader trends in patient-centered care.

Key Market Segments

By Disease Type

• Atopic Dermatitis
• Allergic Contact Dermatitis
• Urticaria
• Others

By Product

• Corticosteroids
• Antihistamines
• Immunosuppressant
• Calcineurin Inhibitors
• Local Anesthetics
• Counterirritants
• Others

By Distribution Channel

• Hospital Pharmacies
• Online Providers
• Drug Stores & Retail Pharmacies

Drivers

Growing Prevalence of Skin Disorders

Increasing prevalence of skin disorders significantly drives the pruritus therapeutics market. Conditions such as eczema and atopic dermatitis affect millions worldwide, leading to a high demand for effective treatments. According to the Life (Basel) Journal, a controlled study conducted in 2021 found that the prevalence rate of eczema among Swedish children was 34%.

Given that itching often accompanies these skin diseases, the burden associated with eczema and atopic dermatitis remains substantial. As awareness of these conditions grows and more patients seek relief from chronic itch, the demand for effective pruritic drugs is expected to increase. Healthcare providers and pharmaceutical companies are likely to focus on developing innovative therapeutic options to meet the needs of affected individuals, further driving market growth.

Restraints

Lack of Standardized Treatment Protocols

High levels of lack of standardized treatment protocols restrain the growth of the pruritus therapeutics market. The absence of universally accepted guidelines for managing itch complicates treatment strategies, leading to inconsistencies in care. Healthcare providers may struggle to determine the most effective therapies for patients suffering from pruritus due to variations in treatment approaches.

This lack of uniformity could impede the adoption of new therapies, as providers may remain hesitant to prescribe untested or less familiar treatments. Furthermore, patients may experience delayed relief or inadequate treatment options, limiting overall market potential. As a result, this restraint is expected to hinder the market’s expansion, particularly in regions where healthcare practices vary widely.

Opportunities

Increase in Clinical Trials Presents Opportunities

Rising number of clinical trials creates significant opportunities for the pruritus therapeutics market. Ongoing research efforts to develop new treatments for chronic itch are expanding rapidly, as pharmaceutical companies invest in innovative solutions. For example, a phase 3 trial conducted by Regeneron Pharmaceuticals, Inc. and Sanofi demonstrated that their drug, Dupixent, had a significant impact on itch within just 12 weeks.

As more clinical trials yield positive results, the introduction of effective new therapies is likely to enhance patient care and increase demand. This surge in research activity is anticipated to lead to a broader range of therapeutic options, thereby driving growth in the pruritus therapeutics market as stakeholders work to address unmet needs and improve treatment outcomes for patients suffering from itch-related conditions.

Impact of Macroeconomic / Geopolitical Factors

Macroeconomic and geopolitical factors significantly influence the market for itch relief treatments. Economic fluctuations can lead to reduced healthcare spending, which may limit the availability of new therapies and negatively impact patient access to essential medications. Rising inflation increases production costs, potentially leading to higher prices for consumers and reduced affordability of treatments. Geopolitical tensions and trade disputes can disrupt the supply chain, affecting the timely delivery of critical ingredients and formulations.

However, growing awareness of dermatological conditions and the increasing prevalence of chronic diseases create substantial demand for effective therapies. Moreover, government initiatives to improve healthcare access and funding for research promote innovation in treatment options. Ultimately, despite challenges, the ongoing commitment to addressing patients’ needs and enhancing treatment accessibility presents a positive outlook for the industry.

Trends

Impact of Approval of New Treatments on the Pruritus Therapeutics Market

Increasing approvals of new treatments are projected to significantly drive growth in the market for itch relief therapies. Regulatory agencies are streamlining the approval processes, allowing innovative solutions to reach patients more quickly. The introduction of novel therapies offers hope for individuals suffering from various forms of pruritus, enhancing the treatment landscape.

For example, in August 2023, the U.S. Food and Drug Administration (FDA) authorized VeopozTM for the treatment of adult and pediatric patients aged one year and older with CHAPLE disease, as reported by Regeneron Pharmaceuticals, Inc. Veopoz represents the first and only treatment specifically recommended for this condition. This approval addressed prior inspection concerns regarding the aflibercept 8 mg Biologics License Application (BLA).

The FDA is likely to take further action on the aflibercept 8 mg BLA in the coming weeks, paving the way for additional treatment options. As new therapies continue to gain approval, the market is expected to expand, offering patients a wider range of effective solutions for managing their conditions.

Regional Analysis

North America is leading the Pruritus Therapeutics Market

North America dominated the market with the highest revenue share of 38.9% owing to several critical factors that highlight the increasing prevalence of skin-related disorders. The rising incidence of chronic skin conditions, such as eczema and psoriasis, has heightened the demand for effective therapeutic options to alleviate itching. Increased awareness of the psychological impact of chronic itching has also prompted healthcare providers to prioritize the treatment of pruritus.

Additionally, advancements in drug development have led to the introduction of innovative therapies specifically targeting chronic spontaneous urticaria (CSU), a severe and unpredictable skin condition. For instance, in January 2021, Novartis announced that the U.S. Food and Drug Administration granted breakthrough therapy designation for a treatment addressing CSU, reflecting the urgent need for effective solutions in this area.

Moreover, growing research on the underlying mechanisms of pruritus has facilitated the development of targeted therapies, further driving market growth. Overall, these dynamics have fostered a robust environment for pruritus therapeutics in North America.

The Asia Pacific region is expected to experience the highest CAGR during the forecast period

In the Asia Pacific region, the pruritus therapeutics market is expected to witness substantial growth during the forecast period. The rising prevalence of dermatological disorders, coupled with an increasing population, is anticipated to drive demand for effective treatment options. Rapid urbanization and changing lifestyles are likely to contribute to higher incidences of allergic reactions and skin irritations, further boosting the market.

Additionally, healthcare systems across the region are projected to enhance their focus on dermatological care, leading to improved access to innovative therapeutics. The growing awareness of the importance of addressing chronic itching, along with increased investments in research and development, is likely to facilitate the introduction of novel therapies.

Furthermore, the expansion of healthcare infrastructure and the rising middle class are expected to enhance patient access to effective treatment solutions. As these trends continue to evolve, the pruritus therapeutics market in the Asia Pacific region is anticipated to flourish, driven by both rising demand and advancements in medical science.

Key Regions and Countries

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia
  • Netherland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • New Zealand
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

Key Players Analysis

The major players in the Pruritus Therapeutics market are actively engaged in the development and introduction of innovative products, as well as implementing strategic initiatives aimed at enhancing their competitive positioning. Key players in the pruritus market drive growth by focusing on innovative treatment options and enhancing patient accessibility. They invest heavily in research and development to create novel therapies, including biologics and topical agents that target underlying causes of itching.

Establishing collaborations with dermatology clinics and healthcare providers facilitates broader distribution and helps to raise awareness about available treatments. Companies actively engage in mergers and acquisitions to diversify their product portfolios and strengthen their market position. Additionally, they focus on expanding into emerging markets, adapting their strategies to meet the unique healthcare needs and regulatory environments of these regions.

Top Key Players in the Pruritus Therapeutics Market

• Teva Pharmaceuticals
• Sanofi
• Pfizer Inc.
• Novartis AG
• Mylan NV
• Ipsen
• GlaxoSmithKline, Plc.
• Bristol-Myers Squibb
• Astellas Pharma
• Actavis Plc

Recent Developments

• In June 2023: Ipsen announced that Bylvay received approval from the United States Food and Drug Administration (FDA) for treating cholestatic pruritus in patients with Alagille syndrome starting at 12 months of age. Bylvay, an ileal bile acid transport inhibitor (IBATi), acts locally in the small intestine with minimal systemic exposure. Previously, in 2021, Bylvay had been authorized as the first medication therapy option for cholestatic pruritus caused by progressive familial intrahepatic cholestasis (PFIC) in Europe and for treating PFIC in the United States. The immediate availability of Bylvay for eligible ALGS patients signifies a significant advancement in treatment options, which is likely to drive growth in the pruritus therapeutics market by addressing unmet medical needs.
• In 2022: Pfizer Inc. launched CIBINQO (abrocitinib), an oral treatment specifically designed for adults with atopic dermatitis. The introduction of this innovative therapy enhances the existing treatment landscape for atopic dermatitis, a condition often associated with pruritus. The availability of effective oral medications is expected to attract more patients seeking relief from symptoms, thereby contributing to the expansion of the pruritus therapeutics market.

Report Scope